SRZN Surrozen, Inc.
$19.00▼ -2.31%
Healthcare
Other
After hours
$19.00▲ +0.00%
Sep 11, 7:30 PM ET
Volume 145.3K
Avg Volume (10D) 212.1K
Key Metrics & Fundamentals
Market Cap
$223.32M
P/E Ratio
–
Div Yield
–%
52W Range
11.25 - 35.00
% vs 50 MA
-15.38%
% vs 200 MA
-21.52%
RSI-14
29.4
MACD Histogram
-0.4800
Beta (1Y vs SPY)
1.50
Free Cash Flow
-$7.43M
Gross Rev
$5.00M
Gross Profit
$5.00M
EBITDA
-$49.57M
COGS
–
Operating Exp
$15.37M
Operating Income
-$10.37M
EBIT
-$10.37M
Pretax Income
$50.18M
Net Income
$50.18M
EPS (Diluted)
-0.41
Price & Volume History
Loading chart…
Recent News
Surrozen Files Investigational New Drug Application for SZN-8141 in Diabetic Macular Edema
MT Newswires · Sep 8, 2026 2:40 PM
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
GlobeNewswire · Sep 8, 2026 12:30 PM
Surrozen to Present at Upcoming Healthcare Investor Conferences
GlobeNewswire · Sep 2, 2026 8:05 PM
William Blair Initiates Surrozen at Outperform
MT Newswires · Aug 20, 2026 10:54 AM
Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · Aug 6, 2026 8:05 PM
Surrozen Highlights Wnt Retina Pipeline, SZN-8141 IND Timeline at H.C. Wainwright
MarketBeat · Jul 22, 2026 8:02 PM
Surrozen to Present at Upcoming Healthcare Investor Conference
GlobeNewswire · Jul 15, 2026 8:05 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See SRZN's money flow as a full page
Social Sentiment
No Reddit posts found for SRZN.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.